A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer By Ogkologos - November 21, 2025 102 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRADE study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Adjuvant Pembrolizumab Plus Chemotherapy Improves DFS in Patients with Newly-Diagnosed, High-Risk... October 1, 2024 Oncology Research Rebounds from Pandemic Low, but Shows Cancer Patients Need... September 10, 2021 EMA Recommends Extension of Therapeutic Indications for Tislelizumab June 7, 2024 Facing the future: “How can a 3-year old understand that her... January 12, 2022 Load more HOT NEWS How a Musician Copes With Life With Metastatic Breast Cancer FDA Granted Accelerated Approval to Belantamab Mafodotin-blmf for Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Ripretinib for the Treatment... EMA Recommends Granting a Conditional Marketing Authorisation for Pemigatinib
